Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members.

ABSTRACT:

Background

Molecular testing (MT) is utilized in neuro-oncology with increasing frequency. The aim of this study was to determine clinical practice patterns to acquire this information, interpret and utilize MT for patient care, and identify unmet needs in the practical clinical application of MT.

Methods

We conducted a voluntary online survey of providers within the Society for Neuro-Oncology (SNO) membership database between March and April 2019.

Results

We received 152 responses out of 2022 SNO members (7.5% of membership). 88.8% of respondents routinely order MT for newly diagnosed gliomas. Of those who do not, testing is preferentially performed in younger patients or those with midline tumors. 82.8% use MT in recurrent gliomas. Other common indications included:

SUBMITTER: Fortin Ensign S 

PROVIDER: S-EPMC8153811 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature